Company Aggregate Debt: BioAtla Inc (BCAB)

The development of BioAtla, Inc. (BCAB) is based on the creation of specific tumor therapy methods, where financial stability is tied to test results. The organization's debt profile shows a peak, after which the current status equals 0.00. BioAtla, Inc. (BCAB) develops biologics that activate within neoplasms to reduce toxicity. The business is currently seeking strategic partners for the joint funding of final-stage clinical trials.

BioAtla Inc - BCAB Company Debts (period 07/04/2022 - 09/06/2026)

Metric breakdowns and analytics for BioAtla, Inc. (BCAB)

- price and consensus price forecast:

Market Price bioatla.com|BCAB - Price Target Chart

- market capitalization data:

Market Capitalization BioAtla Corp|BCAB - Enterprise Value

- book capitalization data:

Net Asset Value per Share BioAtla|BCAB - Company Book Value|Market Value to Book Value bioatla.com|BCAB - Company Total Assets

- debt and liquidity data:

Total Debt to Capital BioAtla, Inc.|BCAB - Long-Term Debt to Equity|Short-Term Debt to Equity bioatla.com|BCAB - Company Total Debt|Debt to Net Assets Ratio BioAtla Corp

Basic company analysis:BioAtla Inc BCAB

To find a balance between the cost and quality of assets, BioAtla, Inc. (BCAB) requires a critical analysis of total debt load, which measures default risk through the ratio of credit obligations to operating revenue. Amid the implementation of costly ESG filtration systems and the optimization of trial logistics, the dynamics of total loans allow for an assessment of the funding stability for the environmental modernization of laboratories without risking capital impairment.

Competitor analysis for BioAtla, Inc.